Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Deal for 100 million doses with additional 100 million through 2023
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The US business faced price erosion due to increased competition.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company has already embarked upon significant expansion in Turkey
Subscribe To Our Newsletter & Stay Updated
